Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 490 results for %s

  1. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

    Technology appraisal guidance
    Published
    13 March 2024
    View recommendations

    Sections for TA955

  2. PulmoVista 500 for monitoring ventilation in critical care (MIB203)

    NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .

    Medtech innovation briefing
    Published
    17 December 2019

  3. AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)

    This advice has been updated and replaced by NICE healthtech guidance 607.

    Withdrawn advice

  4. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

    Medtech innovation briefing
    Published
    9 February 2017

  5. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (HTG423)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

    HealthTech guidance
    Published
    23 November 2016
    View recommendations

    Sections for HTG423

  6. PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection (MIB200)

    NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .

    Medtech innovation briefing
    Published
    9 December 2019

  7. eXroid for internal haemorrhoids (MIB201)

    NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .

    Medtech innovation briefing
    Published
    10 December 2019

  8. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

    Medtech innovation briefing
    Published
    8 April 2020

  9. Key question: effective

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  10. Cost effectiveness of daycare units for treating patients with an acute painful sickle cell episode:- Are daycare units cost effective compared with emergency settings for treating patients with an acute painful sickle cell episode?

    quality of life (HRQoL). Data should be collected using validated measure(s) of HRQoL, including EQ-5D Source guidance details Comes...

    Research recommendation
    Published
    9 June 2015

  11. For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    magnitude. It is recommended that data are collected using validated measure(s) of HRQoL, including EQ-5D. Source guidance details Comes...

    Research recommendation
    Published
    26 October 2020

  12. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    magnitude. It is recommended that data are collected using validated measure(s) of HRQoL,including EQ-5D. Source guidance details Comes...

    Research recommendation
    Published
    9 June 2015

  13. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA373

  14. Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in under 16s (not pregnant or recently pregnant). It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

    NICE guideline
    Published
    19 November 2025

    Sections for NG254

  15. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

    Medtech innovation briefing
    Published
    4 March 2019